AAMU
EPZM

Amundi Asset Management US’s Epizyme, Inc EPZM Stock Holding History

Amundi Asset Management US’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-602,929
Closed -$9.68M – 1667
2020
Q2 		$9.68M Buy
+602,929
New +$10.5M 0.01% 718

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Amundi Asset Management US's EPZM Position: Q3 2020 in Review

Amundi Asset Management US sold out of Epizyme, Inc (EPZM) in Q3 2020, closing a stake of 602,929 shares — an estimated $9.68M sold.

Amundi Asset Management US first reported a position in EPZM in Q2 2020 and held it in 1 quarter. The position peaked at $9.68M in Q2 2020. 151 funds tracked by Wall St. Rank hold EPZM as of Q3 2020.

  • Amundi Asset Management US reported no remaining Epizyme, Inc position as of Q3 2020 after selling out during the quarter.
  • Amundi Asset Management US sold 602,929 Epizyme, Inc shares in Q3 2020, an estimated $9.68M.
  • Amundi Asset Management US first reported a position in Epizyme, Inc in Q2 2020 and held it in 1 quarter.
  • Amundi Asset Management US's Epizyme, Inc position peaked at $9.68M in Q2 2020.
  • 151 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2020.

Based on Amundi Asset Management US's 13F filing for Q3 2020, filed 16 Nov 2020.